Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy

被引:4
作者
Onal, Cem [1 ]
Torun, Nese [2 ]
Guler, Ozan C. [1 ]
Yildirim, Berna A. [1 ]
机构
[1] Baskent Univ, Fac Med, Dept Radiat Oncol, Ankara, Turkey
[2] Baskent Univ, Fac Med, Dept Nucl Med, Ankara, Turkey
关键词
chemoradiotherapy; metabolic response; oesophageal cancer; PET; prognostic factors; POSITRON-EMISSION-TOMOGRAPHY; SQUAMOUS-CELL CARCINOMA; PHASE-III TRIAL; NEOADJUVANT CHEMORADIOTHERAPY; FDG-PET; PATHOLOGICAL RESPONSE; ESOPHAGOGASTRIC JUNCTION; CHEMORADIATION THERAPY; TUMOR RESPONSE; SURGERY;
D O I
10.1097/MNM.0000000000000594
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
BackgroundThis study aimed to assess the efficacy of fluorine-18 fluorodeoxyglucose (F-18-FDG)-PET for predicting overall survival (OS) and disease-free survival (DFS) in oesophageal cancer patients after definitive chemoradiotherapy (CRT) and prognostic importance of metabolic response detected by post-treatment PET at least 3 months after completing CRT.Materials and methodsData from 58 oesophageal cancer patients receiving definitive CRT were retrospectively analysed. Post-treatment F-18-FDG-PET was delivered at a median of 3.2 (range, 3.0-6.4) months after CRT. The impact of metabolic response determined by post-treatment F-18-FDG-PET, maximum post-treatment standardized uptake value (SUVmax) and percent SUV change (pretreatment to post-treatment) on survival was analysed.ResultsThe median follow-up was 19.7 (range, 4.2-91.9) months for all patients and 28.2 (range, 13.7-91.9) months for survivors. The mean pretreatment and post-treatment SUVmax and the median percent SUV decrease were 18.66.4, 6.2 +/- 4.6 and -73% (+13 to -100%). Pretreatment SUVmax was higher in patients with locoregional or distant failure than in those without (P<0.001). Pretreatment SUVmax was lower in patients with a complete response (CR) than in those without a CR (P=0.006). Two-year OS and DFS were higher in patients with CR compared with those without CR (P<0.001). CR rates detected by post-treatment F-18-FDG-PET were lower in patients with lymph node metastases or longer tumours than in those with shorter tumours or no metastases. During multivariate analysis, post-treatment SUVmax was a significant predictor for OS, and post-treatment SUVmax, percent SUV decrease and tumour length were significant prognostic factors for DFS.ConclusionMetabolic response assessed by post-treatment F-18-FDG-PET at least 3 months after CRT showed that post-treatment SUVmax and percent SUV change were important survival predictors.
引用
收藏
页码:1282 / 1289
页数:8
相关论文
共 26 条
[1]   PROSPECTIVE COMPARISON OF SURGERY ALONE AND CHEMORADIOTHERAPY WITH SELECTIVE SURGERY IN RESECTABLE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS [J].
Ariga, Hisanori ;
Nemoto, Kenji ;
Miyazaki, Shukichi ;
Yoshioka, Takashi ;
Ogawa, Yohishiro ;
Sakayauchi, Toru ;
Jingu, Keiichi ;
Miyata, Go ;
Onodera, Ko ;
Ichikawa, Hirofumi ;
Kamei, Takashi ;
Kato, Shunsuke ;
Ishioka, Chikashi ;
Satomi, Susumu ;
Yamada, Shogo .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (02) :348-356
[2]   Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer [J].
Atsumi, Kazushige ;
Nakamura, Katsumasa ;
Abe, Koichiro ;
Hirakawa, Masakazu ;
Shioyama, Yoshiyuki ;
Sasaki, Tomonari ;
Baba, Shingo ;
Isoda, Takuro ;
Ohga, Saiji ;
Yoshitake, Tadamasa ;
Shinoto, Makoto ;
Asai, Kaori ;
Honda, Hiroshi .
JOURNAL OF RADIATION RESEARCH, 2013, 54 (05) :890-898
[3]  
Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
[4]  
Beseth BD, 2000, AM SURGEON, V66, P827
[5]   Can 18F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis [J].
Chen, Yu-mei ;
Pan, Xu-feng ;
Tong, Lin-jun ;
Shi, Yi-ping ;
Chen, Tao .
NUCLEAR MEDICINE COMMUNICATIONS, 2011, 32 (11) :1005-1010
[6]   Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer [J].
Flamen, P ;
Van Cutsem, E ;
Lerut, A ;
Cambier, JP ;
Haustermans, K ;
Bormans, G ;
De Leyn, P ;
Van Raemdonck, D ;
De Wever, W ;
Ectors, N ;
Maes, A ;
Mortelmans, L .
ANNALS OF ONCOLOGY, 2002, 13 (03) :361-368
[7]  
Herszényi L, 2010, EUR REV MED PHARMACO, V14, P249
[8]   Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma [J].
Higuchi, Ichirou ;
Yasuda, Takushi ;
Yano, Masahiko ;
Doki, Yuichirou ;
Miyata, Hiroshi ;
Tatsumi, Mitsuaki ;
Fukunaga, Hironori ;
Takiguchi, Shuji ;
Fujiwara, Yoshiyuki ;
Hatazawa, Jun ;
Monden, Morito .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 136 (01) :205-U114
[9]   Postchemoradiotherapy Positron Emission Tomography Predicts Pathologic Response and Survival in Patients With Esophageal Cancer [J].
Jayachandran, Priya ;
Pai, Reetesh K. ;
Quon, Andrew ;
Graves, Edward ;
Krakow, Trevor E. ;
La, Trang ;
Loo, Billy W., Jr. ;
Koong, Albert C. ;
Chang, Daniel T. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (02) :471-477
[10]   Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma [J].
Jeong, Yuri ;
Kim, Jong Hoon ;
Kim, Sung-Bae ;
Yoon, Dok Hyun ;
Park, Seung Il ;
Kim, Yong Hee ;
Kim, Hyeong Ryul ;
Jung, Hwoon Yong ;
Lee, Gin Hyug ;
Ryu, Jin-Sook .
JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (05) :472-477